WO2005021783A3 - New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se - Google Patents

New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se Download PDF

Info

Publication number
WO2005021783A3
WO2005021783A3 PCT/EP2004/009565 EP2004009565W WO2005021783A3 WO 2005021783 A3 WO2005021783 A3 WO 2005021783A3 EP 2004009565 W EP2004009565 W EP 2004009565W WO 2005021783 A3 WO2005021783 A3 WO 2005021783A3
Authority
WO
WIPO (PCT)
Prior art keywords
notch2
new
function
gain
loss
Prior art date
Application number
PCT/EP2004/009565
Other languages
French (fr)
Other versions
WO2005021783A2 (en
Inventor
Adrian Merlo
Jean-Louis Boulay
Original Assignee
Adrian Merlo
Jean-Louis Boulay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrian Merlo, Jean-Louis Boulay filed Critical Adrian Merlo
Publication of WO2005021783A2 publication Critical patent/WO2005021783A2/en
Publication of WO2005021783A3 publication Critical patent/WO2005021783A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

The invention concerns the new use of gain and loss of Notch2 function by e.g. alterations of Notch2 in brain tumors, especially glioblastomas, astrocytomas and oligodendrogliomas and the new Notch2 genetic alteration of the Notch2 genes per se. In sum, it had been found that, while impaired Notch2 function is a key of oligodendrogliomas, gain of Notch2 function through overexpression is frequently observed in astrocytomas and glioblastomas. By these observations it had been learned that Notch2 may play a dual role in brain tumor development. All these results create opportunities for diagnostic test or new therapeutic useful.
PCT/EP2004/009565 2003-08-30 2004-08-27 New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se WO2005021783A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03019792.5 2003-08-30
EP03019792 2003-08-30

Publications (2)

Publication Number Publication Date
WO2005021783A2 WO2005021783A2 (en) 2005-03-10
WO2005021783A3 true WO2005021783A3 (en) 2005-04-14

Family

ID=34259152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/009565 WO2005021783A2 (en) 2003-08-30 2004-08-27 New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se

Country Status (1)

Country Link
WO (1) WO2005021783A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007474A1 (en) * 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
WO2001025422A2 (en) * 1999-10-07 2001-04-12 Avi Biopharma, Inc. Antisense compositions and cancer-treatment methods
WO2002040716A2 (en) * 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US20030082651A1 (en) * 2000-09-22 2003-05-01 Genentech, Inc. Notch receptor agonists and uses
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007474A1 (en) * 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
WO2001025422A2 (en) * 1999-10-07 2001-04-12 Avi Biopharma, Inc. Antisense compositions and cancer-treatment methods
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US20030082651A1 (en) * 2000-09-22 2003-05-01 Genentech, Inc. Notch receptor agonists and uses
WO2002040716A2 (en) * 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAPOBIANCO A J ET AL: "Neoplastic Transformation by Truncated Alleles of Human NOTCH/TAN and NOTCH 2", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 17, no. 11, November 1997 (1997-11-01), pages 6265 - 6273, XP002266670, ISSN: 0270-7306 *
JANG M-S ET AL: "NOTCH SIGNALING AS A TARGET IN MULTIMODALITY CANCER THERAPY", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 1, February 2000 (2000-02-01), pages 55 - 65, XP009013844, ISSN: 1464-8431 *
LARSSON C ET AL: "THE HUMAN NOTCH1, 2, AND 3 GENES ARE LOCATED AT CHROMOSOME POSITIONS 9Q34, 1P13-P11, AND 19P13.2-P13.1 IN REGIONS OF NEOPLASIA-ASSOCIATED TRANSLOCATION", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 24, no. 2, 15 November 1994 (1994-11-15), pages 253 - 258, XP000670019, ISSN: 0888-7543 *
LU R Q ET AL: "Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 19, 9 November 2001 (2001-11-09), pages 10851 - 10856, XP002267119, ISSN: 0027-8424 *
ZLOBIN A ET AL: "TOWARD THE RATIONAL DESIGN OF CELL FATE MODIFIERS: NOTCH SIGNALING AS A TARGET FOR NOVEL BIOPHARMACEUTICALS", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, BOCA RATON,FL, US, vol. 1, no. 1, July 2000 (2000-07-01), pages 83 - 106, XP008004456, ISSN: 1389-2010 *

Also Published As

Publication number Publication date
WO2005021783A2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2001097829A3 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2006009805A3 (en) Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
WO2005025511A3 (en) Potassium channel mediated delivery of agents through the blood-brain barrier
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2006037462A3 (en) Cancer markers
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2005032495A3 (en) Gene expression profiles and methods of use
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2007149521A3 (en) Nucleotide motifs providing localization elements and methods of use
WO2006066154A3 (en) Casein kinase 2 antisense therapy
WO2005021783A3 (en) New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2005023186A3 (en) Methods of identifying agents that inhibit the growth of cancer cells
WO2003018629A8 (en) Cage antigen
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2005046607A3 (en) Combinations for the treatment of proliferative diseases
WO2004089409A3 (en) Agent for the photodynamic diagnosis and therapy of malignant tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase